Stock Events

Stock Events

ASLAN Pharmaceuticals 

$0.6
18
-$0.1-14.27% Thursday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

29AprExpected
Q1 2022
Q2 2022
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
-0.87
-0.58
-0.29
-0
Expected EPS
-0.61
Actual EPS
-0.78

Financials

-368.5%Profit Margin
Unprofitable
2018
2019
2020
2021
2022
2023
12MRevenue
-44.22MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ASLN. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Incyte
INCY
Mkt Cap18.35B
Incyte Corporation focuses on the discovery, development, and commercialization of various therapeutics, including those in oncology, which competes with ASLAN's cancer treatment pipeline.
Exelixis
EXEL
Mkt Cap10.41B
Exelixis, Inc. is focused on the discovery, development, and commercialization of new medicines for the treatment of cancer, including therapies that could directly compete with ASLAN's products.
Array Technologies
ARRY
Mkt Cap1.32B
Array BioPharma, acquired by Pfizer, focuses on the development of drugs for the treatment of cancer, including targeted small molecule drugs that compete with ASLAN's portfolio.
Puma Biotechnology
PBYI
Mkt Cap256.89M
Puma Biotechnology is focused on the development and commercialization of innovative products to enhance cancer care, competing with ASLAN Pharmaceuticals in the oncology sector.

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Show more...
CEO
Employees
35
Country
US
ISIN
US04522R3093
WKN
000A2JN62

Listings

0 Comments

Share your thoughts

FAQ

What is ASLAN Pharmaceuticals stock price today?▼
The current price of ASLN is $0.6 USD — it has decreased by -14.27% in the past 24 hours. Watch ASLAN Pharmaceuticals stock price performance more closely on the chart.
What is ASLAN Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ASLAN Pharmaceuticals stocks are traded under the ticker ASLN.
What were ASLAN Pharmaceuticals earnings last quarter?▼
ASLN earnings for the last quarter are -0.78 USD per share, whereas the estimation was -0.61 USD resulting in a -27.87% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is ASLAN Pharmaceuticals revenue for the last year?▼
ASLAN Pharmaceuticals revenue for the last year amounts to 12M USD.
What is ASLAN Pharmaceuticals net income for the last year?▼
ASLN net income for the last year is -44.22M USD.
How many employees does ASLAN Pharmaceuticals have?▼
As of April 01, 2026, the company has 35 employees.
In which sector is ASLAN Pharmaceuticals located?▼
ASLAN Pharmaceuticals operates in the Professional, Scientific, and Technical Services sector.
When did ASLAN Pharmaceuticals complete a stock split?▼
The last stock split for ASLAN Pharmaceuticals was on July 03, 2024 with a ratio of 1:8.
Where is ASLAN Pharmaceuticals headquartered?▼
ASLAN Pharmaceuticals is headquartered in 190 Elgin Avenue, US.